Dexmedetomidine is an a2-adrenergic receptor agonist with an eight-fold greater affinity for the a2-adrenergic receptor than its sister drug clonidine. It is a sedative that is clear, colourless and tasteless and has been used in children for a number of years. Advantages of Dexmedetomidine over other agents used in paediatrics include: ease of administration; reduction in postoperative analgesic requirements; and reduction in postoperative nausea and vomiting (PONV).
- Increasing the interval between repeated anesthetic exposures reduces long‐lasting synaptic changes in late post‐natal mice
- Tau Contributes to Sevoflurane-induced Neurocognitive Impairment in Neonatal Mice
- Neonatal exposure to sevoflurane expands the window of vulnerability to adverse effects of subsequent exposure to sevoflurane and alters hippocampal morphology via decitabine-sensitive mechanisms
- Sevoflurane Post-Conditioning Ameliorates Neuronal Deficits and Axon Demyelination After Neonatal Hypoxic Ischemic Brain Injury: Role of Microglia/Macrophage
- Behavior and Regional Cortical BOLD Signal Fluctuations Are Altered in Adult Rabbits After Neonatal Volatile Anesthetic Exposure